Titelbild

Press releases

2022-02-15 – Press release

Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

    • Dr. de Min brings over 25 years’ experience in drug development in both big pharma and biotech
    • She will drive the advancement of Topas’ development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for treatment of celiac disease

read more …

2021-07-29 – Press release

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

  • Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases
  • Initial clinical data for lead program, TPM203, in pemphigus vulgaris expected this year; second program, TPM502, planned to enter clinic by year end for celiac disease
  • In strong support of Topas’ technology and programs, all existing investors - BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III - participated in the extension

read more …

2020-10-19 – Press release

Topas Therapeutics erhält EUR 22 Mio. (USD 26 Mio.) aus Serie-B-Finanzierungsrunde

  • Finanzierungsrunde wurde unter Beteiligung aller bestehenden Investoren von den neuen Kapitalgebern Vesalius BioCapital III und BioMedPartners angeführt
  • Die liquiden Mittel sollen der Weiterentwicklung der innovativen Pipeline des Unternehmens dienen, die auf der Topas Partikel-Konjugat-Technologieplattform (Topas Particle Conjugates, TPCs) basiert
    • Lead-Kandidat TPM203 befindet sich in der klinischen Entwicklung zur Behandlung von Pemphigus vulgaris (PV)
    • Zweiter Kandidat TPM501, der auf die erste klinische Studie zur Behandlung von Zöliakie vorbereitet wird
  • Vertreter der beiden neuen Investoren werden in den Aufsichtsrat berufen; Dr. med. Erich F. Greiner wird zum Aufsichtsratsvorsitzenden ernannt

read more …

2020-10-19 – Press release

Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing

  • Co-led by new investors, Vesalius BioCapital III and BioMedPartners, with participation from all existing investors
  • Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform
    • Lead program TPM203 in clinical development for pemphigus vulgaris
    • Second program, TPM501, progressing towards clinic for treatment of celiac disease
  • New investors join Supervisory Board; Erich F. Greiner, M.D., becomes Chairman

read more …

2020-10-19 – Press release

Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer

  • Highly accomplished biotech executive with nearly two decades of industry leadership experience
  • Topas is advancing its pipeline based on its Topas Particle Conjugates technology platform, with lead program TPM203 in clinical development for treatment of pemphigus vulgaris and second program, TPM501, progressing towards clinic for treatment of celiac disease

read more …